These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 31821195)

  • 1. Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials.
    Liao YWB; Wang TKM
    Coron Artery Dis; 2020 May; 31(3):260-265. PubMed ID: 31821195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial.
    Oldgren J; Steg PG; Hohnloser SH; Lip GYH; Kimura T; Nordaby M; Brueckmann M; Kleine E; Ten Berg JM; Bhatt DL; Cannon CP
    Eur Heart J; 2019 May; 40(19):1553-1562. PubMed ID: 30793734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy.
    Desai A; Escamilla-Ocanas C; Dilip D; Saber H; Damani R
    J Stroke Cerebrovasc Dis; 2021 Apr; 30(4):105654. PubMed ID: 33578352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation].
    Darius H
    Dtsch Med Wochenschr; 2020 Jul; 145(14):978-986. PubMed ID: 32668469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
    Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
    Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
    Windecker S; Lopes RD; Massaro T; Jones-Burton C; Granger CB; Aronson R; Heizer G; Goodman SG; Darius H; Jones WS; Aschermann M; Brieger D; Cura F; Engstrøm T; Fridrich V; Halvorsen S; Huber K; Kang HJ; Leiva-Pons JL; Lewis BS; Malaga G; Meneveau N; Merkely B; Milicic D; Morais J; Potpara TS; Raev D; Sabaté M; de Waha-Thiele S; Welsh RC; Xavier D; Mehran R; Alexander JH;
    Circulation; 2019 Dec; 140(23):1921-1932. PubMed ID: 31557056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial).
    Ten Berg JM; Steg PG; Bhatt DL; Hohnloser SH; de Veer A; Nordaby M; Miede C; Kimura T; Lip GYH; Oldgren J; Cannon CP;
    Am J Cardiol; 2020 Mar; 125(5):735-743. PubMed ID: 31924322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.
    Cannon CP; Gropper S; Bhatt DL; Ellis SG; Kimura T; Lip GY; Steg PG; Ten Berg JM; Manassie J; Kreuzer J; Blatchford J; Massaro JM; Brueckmann M; Ferreiros Ripoll E; Oldgren J; Hohnloser SH;
    Clin Cardiol; 2016 Oct; 39(10):555-564. PubMed ID: 27565018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials.
    Ray A; Najmi A; Khandelwal G; Jhaj R; Sadasivam B
    Cardiovasc Drugs Ther; 2021 Jun; 35(3):561-574. PubMed ID: 32816142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Dabigatran Plus a P2Y
    De Caterina R; Procopio A; Lopez Sendon JL; Raev D; Mehta SR; Opolski G; Oldgren J; Steg PG; Hohnloser SH; Lip GYH; Kimura T; Kleine E; Ten Berg JM; Bhatt DL; Miede C; Nordaby M; Cannon CP;
    Am J Med; 2020 Nov; 133(11):1302-1312. PubMed ID: 32389658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint.
    Rubboli A; Agewall S; Huber K; Lip GY
    Int J Cardiol; 2015 Oct; 196():133-8. PubMed ID: 26093527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic strategies in patients needing oral anticoagulation undergoing percutaneous coronary intervention: A network meta-analysis.
    Saglietto A; D'Ascenzo F; Errigo D; Leonardi S; Dewilde WJ; Conrotto F; Omedè P; Montefusco A; Angelini F; De Filippo O; Bianco M; Gallone G; Bruno F; Zaccaro L; Giannini F; Latib A; Colombo A; Costa F; De Ferrari GM
    Catheter Cardiovasc Interv; 2021 Mar; 97(4):581-588. PubMed ID: 32790145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials.
    Potpara TS; Mujovic N; Proietti M; Dagres N; Hindricks G; Collet JP; Valgimigli M; Heidbuchel H; Lip GYH
    Europace; 2020 Jan; 22(1):33-46. PubMed ID: 31603196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
    Berry NC; Mauri L; Steg PG; Bhatt DL; Hohnloser SH; Nordaby M; Miede C; Kimura T; Lip GYH; Oldgren J; Ten Berg JM; Cannon CP
    Circ Cardiovasc Interv; 2020 Apr; 13(4):e008349. PubMed ID: 32252548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
    Lopes RD; Heizer G; Aronson R; Vora AN; Massaro T; Mehran R; Goodman SG; Windecker S; Darius H; Li J; Averkov O; Bahit MC; Berwanger O; Budaj A; Hijazi Z; Parkhomenko A; Sinnaeve P; Storey RF; Thiele H; Vinereanu D; Granger CB; Alexander JH;
    N Engl J Med; 2019 Apr; 380(16):1509-1524. PubMed ID: 30883055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials.
    Li J; Wang Q; Wu C; Qu X; Zhang L; He X; Ma S; Qiu M; Wang X
    Cardiology; 2023; 148(4):363-373. PubMed ID: 37094558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
    Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
    Cannon CP; Bhatt DL; Oldgren J; Lip GYH; Ellis SG; Kimura T; Maeng M; Merkely B; Zeymer U; Gropper S; Nordaby M; Kleine E; Harper R; Manassie J; Januzzi JL; Ten Berg JM; Steg PG; Hohnloser SH;
    N Engl J Med; 2017 Oct; 377(16):1513-1524. PubMed ID: 28844193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Fanaroff AC; Lopes RD
    Prog Cardiovasc Dis; 2021; 69():11-17. PubMed ID: 34883097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of concomitant antiplatelet therapy in patients with nonvalvular atrial fibrillation initiating non-vitamin K antagonists.
    Elvira Ruiz G; Caro Martínez C; Flores Blanco PJ; Cerezo Manchado JJ; Albendín Iglesias H; Lova Navarro A; Arregui Montoya F; García Alberola A; Pascual Figal DA; Bailén Lorenzo JL; Manzano-Fernández S
    Eur J Clin Invest; 2019 Oct; 49(10):e13161. PubMed ID: 31449685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.